title: Dynamics of JAK2 V617F allele burden of CD34+ haematopoietic progenitor cells in patients treated with ruxolitinib.
authors.affiliation: Haematology Department, Hospital del Mar, Barcelona, Spain.|Universitat Autònoma de Barcelona, Barcelona, Spain.|Grup de Recerca Clínica Aplicada en Neoplàsies Hematològiques-IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
authors.forename: Anna
authors.initials: A
authors.lastname: Angona
authors.affiliation: Haematology Department, Hospital del Mar, Barcelona, Spain. 95967@parcdesalutmar.cat.|Universitat Autònoma de Barcelona, Barcelona, Spain. 95967@parcdesalutmar.cat.|Grup de Recerca Clínica Aplicada en Neoplàsies Hematològiques-IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. 95967@parcdesalutmar.cat.
authors.forename: Alberto
authors.initials: A
authors.lastname: Alvarez-Larrán
authors.affiliation: Grup de Recerca Clínica Aplicada en Neoplàsies Hematològiques-IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.|Pathology Department, Hospital del Mar, Barcelona, Spain.|Universitat Pompeu Fabra, Barcelona, Spain.
authors.forename: Beatriz
authors.initials: B
authors.lastname: Bellosillo
authors.affiliation: Grup de Recerca Clínica Aplicada en Neoplàsies Hematològiques-IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.|Pathology Department, Hospital del Mar, Barcelona, Spain.
authors.forename: Raquel
authors.initials: R
authors.lastname: Longarón
authors.affiliation: Universitat Autònoma de Barcelona, Barcelona, Spain.|Grup de Recerca Clínica Aplicada en Neoplàsies Hematològiques-IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
authors.forename: Concepción
authors.initials: C
authors.lastname: Fernández-Rodríguez
authors.affiliation: Haematology Department, Hospital del Mar, Barcelona, Spain.|Grup de Recerca Clínica Aplicada en Neoplàsies Hematològiques-IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
authors.forename: Carlos
authors.initials: C
authors.lastname: Besses
mesh_terms: D000483:Alleles; D018952:Antigens, CD34 / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004268:DNA-Binding Proteins / Q000235:genetics; D049308:Dioxygenases; D006098:Granulocytes / Q000378:metabolism; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D009154:Mutation / Q000235:genetics; D009196:Myeloproliferative Disorders / Q000188:drug therapy* / Q000235:genetics*; D009570:Nitriles; D011518:Proto-Oncogene Proteins / Q000235:genetics; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines
chemical_list: D018952:Antigens, CD34; D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; D009570:Nitriles; D011518:Proto-Oncogene Proteins; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib; D049308:Dioxygenases; C541081:TET2 protein, human; C507924:JAK2 protein, human; D053614:Janus Kinase 2
keywords: JAK2 V617F; additional mutations; myeloproliferative disorders; progenitor cells; ruxolitinib